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A major challenge for medical science is the ability to relate find-
ings in cell cultures and animal models back to the patient. In the
current setting of technological advance, we now have the abil-
ity to over-express or knockdown the expression of specific genes,
and we are able to challenge cells with an array of putative fac-
tors, but are we able to translate these findings back to the patient?
This collection of reviews (which includes unpublished data) aims
to summarise our current understanding of acute liver failure
(ALF). This has been a daunting task for authors, as ALF is a
highly variable condition, whose outcome is determined by a vari-
ety of inter-related factors. As such, we are unable to present an
exhaustive review of all putative cellular and molecular processes.
Nevertherless, all authors have concisely and critically appraised
the available literature on the different aspects of ALF, which
include ALF pathogenesis, the role of immunity, the diagnostic
and treatment strategies, and the role of prognostic algorithms in
use today.
ALF can be caused by toxins, infections, metabolic and
genetic diseases, but irrespective of etiology, ALF is character-
ized by the massive and confluent loss of functioning hep-
atocytes. In their review, Bantel and Schulze-Osthoff (2012)
presented putative mechanisms of hepatocyte cell death, and
discussed their relevance in patients with ALF. They propose
that the degree of hepatocyte cell death may be a surrogate
biomarker of ALF severity, and may be utilized as a predictor
of ALF outcomes. This is supported findings of etiology depen-
dent modes of hepatocyte cell death in ALF (Bechmann et al.,
2010).
While the excessive consumption of alcohol is generally asso-
ciated with the development of chronic liver disease, the acute
intoxication of alcohol can also lead to ALF, or predispose an
individual to ALF (from other etiology). It remains unclear how
acute alcohol consumption could lead to ALF, although Massey
and Arteel (2012) have presented novel data on the possible
contributions by PAI-1, fibrins, and integrins.
The importance and role of miRNAs in the development or
progression of ALF is only coming to fore. Recent studies show
that miRNAs are differentially expressed in liver diseases, and
may have a direct pathogenic role in ALF. Elfimova et al. (2012)
presented an elegant review of currently identified miRNAs in
liver disease, and highlighted the over-expression of miR-122 in
patients with acute liver injury. It would be interesting to evaluate
if miR-122 could serve as a prognostic biomarker in patients with
ALF.
ALF is associated with a massive immune response, with
recruitment of inflammatory cells from the peripheral circula-
tion into the liver, the activation of stress and death receptors,
and the clearance of apoptotic/necrotic debris, that lead to the
perpetuation of hepatic inflammation and injury. In their review,
Zimmermann et al. (2012) described the importance of resi-
dent macrophages (Kupffer cells) and recruited monocytes in the
pathogenesis of ALF. When activated by danger signals, these
cells secrete pro-inflammatory cytokines TNFa and upregulate
expression of FasL, which in concert, enhance hepatocyte death.
Activated immune cells, as well as dying hepatocytes and stromal
cells are capable of secreting chemokines that lead to the further
recruitment and retention of effector T and NK cells that amplify
the inflammatory response. Saiman and Friedman (2012) dis-
cussed the role of putative chemokines in ALF, which remains to
be fully elucidated as studies have demonstrated apparently con-
flicting results. This could be related to differences in underlying
etiology, and/or to the role of other immune subsets such as reg-
ulatory T cells. The use of chemokine inhibitors in treating ALF
is attractive, but remains out of reach of clinical applications at
this stage, as we have yet to fully understand the roles of specific
chemokines and/or immune subsets in the patient.
The liver exhibits a remarkable ability to regenerate itself after
an acute insult. For example, after liver resection in man, or
partial hepatectomy in rodents, the liver is capable of efficient
regeneration that leads to the spontaneous restoration of liver
mass and function. During fulminant ALF, however, the loss of
hepatocyte mass is just too massive and outweighs the intrinsic
ability of residual hepatocytes to regenerate sufficiently. As such,
an alternative source of hepatocytes and cholangiocytes is neces-
sary to help restore liver function. Best et al. (2013) reviewed the
role of the liver progenitor cell population (LPC) during acute
liver injury. They provided examples from preclinical models to
show that the LPC is an active participant of liver regeneration,
and discussed putative signaling pathways considered important
for LPC responses. One such signaling pathway is the Hedgehog
pathway that plays an important role tissue development, but has
recently been reported to be critical for liver regeneration after
partial hepatectomy in mice. Recent data from man confirm that
the LPC population is expanded during ALF, and may be useful
in predicting the outcome of ALF. Another cell type, which may
be involved in ALF are hepatic stellate cell. These could also con-
tribute to liver regeneration by alteration of extracellular matrix
(Dechêne et al., 2010).
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Whether LPC or stem cells (such as mesenchymal stem
cells, MSC or hematopoietic stem cells) may be effective in
treating ALF remains to be seen. Hepatocyte transplantation
has been successful in rodents, while pre-differentiated MSC
have been shown by Christ and Brückner (2012) to amelio-
rate acetaminophen-induced liver injury.MSC exhibits additional
anti-inflammatory properties, thus, may lead to an attenuated
inflammatory response. Chamulitrat et al. (2012) suggest a
derivative of ursodeoxycholic acid as possible novel treatment
option. For the majority of individuals with fulminant ALF, how-
ever, a liver transplant (LTx) remains the only curative option.
Despite the availability of numerous scoring systems, they are
generally poor at predicting survival (i.e., those who do not need
a liver transplant). These difficult issues faced by transplant physi-
cians are reviewed extensively by Hadem et al. (2012). Unknown
reasons for ALF further complicate clinical handling. Drebber
et al. (2013) identified hepatitis E virus as cause for some pre-
viously unclear ALF in cases in Europe. Thus, this neglected
etiology should also be considered in Europe and not only in
Asian or African countries.
In summary, ALF is a challenging disease with many eti-
ologies and mechanisms of injury. A better understanding of
the complex pathogenic mechanisms involved is necessary for
us to identify new targets for therapy, and/or better predictors
of outcome. Studies will be needed to dissect the contributions
of individual cell types (recruited vs. resident; parenchymal vs.
non-parenchymal) during ALF and regeneration. Future research
should focus on novel treatment strategies, including the use of
stem cells and LPCs.
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